نتایج جستجو برای: myelodysplastic syndromes

تعداد نتایج: 86513  

Journal: :International Journal of Hematology 2017

2014
Valeria Visconte Carmine Selleri Jaroslaw P. Maciejewski Ramon V. Tiu

Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorders characterized by inefficient hematopoiesis, hypercellular bone marrow, dysplasia of blood cells and cytopenias. Most patients are diagnosed in their late 60s to early 70s. MDS is a risk factor for the development of acute myeloid leukemia which can occur in 10-15% of patients with MDS. A variety of pathophysiologic mech...

Journal: :Cancer control : journal of the Moffitt Cancer Center 2008
Luca Malcovati Stephen D Nimer

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematologic disorders characterized by ineffective hematopoiesis and an increased risk of developing acute myelogenous leukemia (AML). Accurate diagnosis of MDS can be difficult, and its classification requires evaluation of cytopenias, bone marrow morphology, blast percentage, and cytogenetics. These factors, as well as patient...

2014
Valeria Visconte Ali Tabarroki Li Zhang Yvonne Parker Edy Hasrouni Reda Mahfouz Kyoichi Isono Haruhiko Koseki Mikkael A Sekeres Yogen Saunthararajah John Barnard Daniel Lindner Heesun J Rogers Ramon V Tiu

Background: The presence of somatic mutations in splicing factor 3b subunit 1 (SF3B1) in patients with Myelodysplastic syndromes with ring sideroblasts (MDS-RS) highlights the importance of the RNA-splicing machinery in MDS. We previously reported the presence of bone marrow (BM) RS in Sf3b1 heterozygous (Sf3b1) mice which are rarely found in mouse models of MDS. Sf3b1 mice were originally engi...

Journal: :Internal medicine 2001
M Tomonaga

Myelodysplastic syndromes (MDS)are clinically characterized by morphological dysplasias of blood cells and cytopenias of variable combinations due to ineffective hematopoiesis (1). They often transform into acute myeloid leukemia (AML) as designated preleukemic syndromes. About 60% of cases with MDScarry a non-randomchromosomeabnormality such as -7, 7q-, -5, 5q-, 20qetc and/or complex abnormali...

Journal: :Cancer control : journal of the Moffitt Cancer Center 2004
Richard Stone

Cancer Control 7 but this approach is unlikely to change the natural history of the disorder. Despite the recent approval of azacitidine, supportive care alone will remain an important treatment option for many patients with MDS. Supportive care consists of transfusions for symptomatic anemia or symptomatic thrombocytopenia, treatment of infections with antibiotics,and growth factors designed t...

Journal: :Cell cycle 2010
Daniel T Starczynowski Aly Karsan

Words: 686 Myelodysplastic syndromes (MDS) are a family of heterogeneous clonal hematological malignancies defined by peripheral cytopenias, a hypercellular or normal

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید